Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Ziopharm Falls After Ending Test of Top Drug Candidate

Ziopharm Oncology Inc., a maker of experimental cancer treatments, tumbled the most in seven years in New York trading after saying it would end plans to develop its lead drug candidate for soft tissue tumors.

The company said it would shift its focus toward other targets after the drug, palifosfamide, failed to meet its primary goals in a study. In a statement today, New York-based Ziopharm announced a restructuring to “align staffing to current objectives.” The shares dropped 65 percent to $1.82 at 4 p.m. New York time, their biggest one-day decline since November 2005.

Ziopharm shares had risen 23 percent for the year through yesterday as Chief Executive Officer Jonathan Lewis said he was in talks with other drugmakers to market palifosfamide. The compound was in late-stage trials as a treatment for soft-tissue sarcoma, a cancer of the muscle, fat and other body tissues. The disease kills about 3,900 people a year in the U.S., according to the National Cancer Institute.

“It is imperative that the company rapidly focus its resources and efforts on our highly promising synthetic biology programs,” Lewis said in today’s statement. Those programs include therapies that “represent the next-generation in biotechnology.”

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.